Pseudo-CT MRI sequences to detect bone lesions in multiple myeloma
Evaluation of Optimised Whole-body MRI Examinations Incorporating "Pseudo-scanner" Sequences (ZTE, "Zero Echo Time" AND Lava Flex) for the Detection of Bone Lesions in Multiple Myeloma
This tests whether new 'pseudo-CT' MRI sequences can detect bone lesions during a single whole-body MRI in people with newly diagnosed multiple myeloma.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 45 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Brussels) |
| Trial ID | NCT06988020 on ClinicalTrials.gov |
What this trial studies
The protocol adds Zero Echo Time and Lava Flex Low Flip Angle "pseudo-CT" sequences into whole-body MRI to visualize mineral bone in addition to marrow. These sequences incorporate deep-learning denoising and chemical-shift correction to reduce noise and artifact and improve visualization of osteolysis. Newly diagnosed multiple myeloma patients requiring staging will undergo whole-body MRI with the pseudo-CT sequences and imaging results will be compared to standard imaging and clinical reference standards. The aim is to determine whether a single, non‑irradiating MRI exam can reliably show both marrow involvement and osteolytic lesions.
Who should consider this trial
Good fit: Ideal candidates are adults with newly diagnosed multiple myeloma who need baseline bone staging, can safely undergo MRI (no incompatible implants, not pregnant), and are not already designated to have PET/CT as the preferred imaging.
Not a fit: Patients with MRI-incompatible implants, severe claustrophobia, pregnancy, those with recurrent disease after intensive treatment, or those for whom PET/CT is the indicated imaging will likely not benefit or be eligible.
Why it matters
Potential benefit: If successful, this could allow patients to have one radiation-free whole-body MRI that shows both marrow disease and bone loss, simplifying staging and reducing CT/PET-CT exposure.
How similar studies have performed: Early pilot work has shown promising diagnostic performance for pseudo-CT sequences in detecting osteolytic lesions, but whole-body MRI integration with deep-learning corrections is still relatively new and not yet widely validated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patient with newly diagnosed multiple myeloma, for whom bone imaging is required for staging. * Recurrent patient after intensive treatment (high dose chemotherapy, bone marrow transplant, etc.). * Patient requiring a PET / CT considered as the technique of choice in these stages of the disease. Exclusion Criteria: * Implanted material incompatible with MRI. * Severe claustrophobia. * Pregnant women
Where this trial is running
Brussels
- Cliniques universitaires Saint-Luc — Brussels, Belgium (Recruiting)
Study contacts
- Principal investigator: Frédéric Lecouvet — Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Study coordinator: Frédéric Lecouvet
- Email: frederic.lecouvet@saintluc.uclouvain.be
- Phone: +3227642793
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.